A Phase 2 interventional study of Brentuximab Vedotin and Rituximab in Diffuse Large B-cell Lymphoma Refractory and Follicular B-cell Non-Hodgkin's Lymphoma, sponsored by Seagen Inc.. Terminated at 50 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-16.
Sponsored by Seagen Inc. (part of Pfizer) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Lymphoma, Large B-Cell, Diffuse by Pfizer — none open to participants now, 1 under way, 1 of them phase 3. Lymphoma, Large B-Cell, Diffuse · Pfizer.
Among the 25 studies in Lymphoma, Large B-Cell, Diffuse by Pfizer, this one is the 20th largest by enrollment, is one of 3 that started in 2015, is one of 9 in phase 2, and was the 13th registered.
1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.
Browse Lymphoma, Large B-Cell, Diffuse studies →None of the 25 studies in Lymphoma, Large B-Cell, Diffuse by Pfizer is open now. The open studies under Lymphoma, Large B-Cell, Diffuse, anywhere →
Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 11 · Phase 3 3
First in 2006; this study’s year is marked. 3 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 25 is below the median of 44 across 1,501 interventional studies indexed under Lymphoma, Large B-Cell, Diffuse.
Median enrollment 58 across the 25 interventional studies. Of the 23 that completed or were terminated, 10 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Seagen Inc., one of the names counted as Pfizer. Under that name alone:
Seagen Inc. is the lead sponsor of 88 studies on the registry; 1 is open to participants now.
Of its 27 completed or terminated interventional studies of FDA-regulated products, 14 (52%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 25 studies in Lymphoma, Large B-Cell, Diffuse by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a randomized, open-label, multicenter, Phase 2 clinical trial designed to evaluate the efficacy and safety of brentuximab vedotin in combination with rituximab and bendamustine for the treatment of patients with relapsed or refractory CD30-positive diffuse large B-cell lymphoma (DLBCL) after failure of second-line salvage therapy or as second-line treatment in patients ineligible for autologous stem cell transplant (ASCT).
Patients will be randomized in a 1:1 manner to receive rituximab plus bendamustine with or without brentuximab vedotin. Patients who respond to combination treatment containing brentuximab vedotin and do not experience excessive toxicity may receive additional single-agent brentuximab vedotin following combination treatment, for up to an additional 10 cycles (up to 16 total cycles of treatment).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients must have disease following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects randomized to the brentuximab vedotin arm will receive IV infusions of brentuximab vedotin followed by bendamustine on day 1, and rituximab followed by bendamustine on day 2 of each 21 day cycle.
Drug: Brentuximab Vedotin · Drug: Rituximab · Drug: Bendamustine
Subjects randomized to the control arm will receive IV infusions of rituximab on day 1 or day 2 and bendamustine on both days 1 and 2 of each 21 day cycle.
Drug: Rituximab · Drug: Bendamustine
Also known as: Adcetris
Also known as: Rituxan
Also known as: Treanda
Objective Response Rate (ORR)
ORR is defined as the percentage of patients who achieve a Complete Response (CR) (including Complete Metabolic Response (CMR)) or Partial Response (PR) (including Partial Metabolic Response (PMR)) as best response to combination therapy on study
Time frame: Approximately 1 year
Progression-free Survival (PFS)
PFS is defined as the time from randomization to disease progression/relapse, receipt of subsequent lymphoma chemotherapy other than the components of the study treatment regimen, or death from any cause, whichever occurs first.
Time frame: Up to 11.8 months
Complete Remission (CR) Rate
CRR is the proportion of patients who achieve CR (including Complete Metabolic Response (CMR)) as best response to combination therapy on study.
Time frame: Approximately 1 year
Duration of Response (DOR)
DOR is defined as the time from first observation of response to disease progression/relapse, receipt of subsequent lymphoma chemotherapy other than the components of the study treatment regimen, or death from any cause, whichever occurs first.
Time frame: Up to 10.5 months
Overall Survival (OS)
OS is defined as the time randomization to death from any cause
Time frame: Up to 1.5 years
Number and Severity of Adverse Events (AEs)
All AEs are included in the summaries, unless treatment-emergent is specified.
Time frame: Approximately 1 year
| Milestone | Rituximab, Bendamustine Control | Brentuximab Vedotin Plus Rituximab Plus Bendamustine |
|---|---|---|
| Started | 12 | 13 |
| Completed | 5 | 1 |
| Not completed | 7 | 12 |
| Withdrew: Progressive disease | 2 | 3 |
| Withdrew: Adverse event | 1 | 5 |
| Withdrew: Physician decision | 1 | 3 |
| Withdrew: Study termination by sponsor | 2 | 1 |
| Withdrew: Other, non-ae | 1 | 0 |
| Milestone | Rituximab, Bendamustine Control | Brentuximab Vedotin Plus Rituximab Plus Bendamustine |
|---|---|---|
| Started | 12 | 13 |
| Completed | 1 | 1 |
| Not completed | 11 | 12 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Withdrew: Study termination by sponsor | 6 | 4 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Death | 2 | 5 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Progressive disease | 2 | 0 |
| Withdrew: Physician decision | 0 | 1 |
ORR is defined as the percentage of patients who achieve a Complete Response (CR) (including Complete Metabolic Response (CMR)) or Partial Response (PR) (including Partial Metabolic Response (PMR)) as best response to combination therapy on study
| percentage of participants | Rituximab, Bendamustine Control | Brentuximab Vedotin Plus Rituximab Plus Bendamustine |
|---|---|---|
| Objective Response Rate (ORR) | 91.7 (61.5 to 99.8) | 61.5 (31.6 to 86.1) |
PFS is defined as the time from randomization to disease progression/relapse, receipt of subsequent lymphoma chemotherapy other than the components of the study treatment regimen, or death from any cause, whichever occurs first.
| months | Rituximab, Bendamustine Control | Brentuximab Vedotin Plus Rituximab Plus Bendamustine |
|---|---|---|
| Progression-free Survival (PFS) | 4.9 (1.6 to 11.8) | 3.7 (0.8 to 11.5) |
CRR is the proportion of patients who achieve CR (including Complete Metabolic Response (CMR)) as best response to combination therapy on study.
| Participants | Rituximab, Bendamustine Control | Brentuximab Vedotin Plus Rituximab Plus Bendamustine |
|---|---|---|
| Complete Remission (CR) Rate | 8 | 7 |
DOR is defined as the time from first observation of response to disease progression/relapse, receipt of subsequent lymphoma chemotherapy other than the components of the study treatment regimen, or death from any cause, whichever occurs first.
| months | Rituximab, Bendamustine Control | Brentuximab Vedotin Plus Rituximab Plus Bendamustine |
|---|---|---|
| Duration of Response (DOR) | 3.7 (0.0 to 10.5) | 4.1 (0.0 to 10.1) |
OS is defined as the time randomization to death from any cause
| months | Rituximab, Bendamustine Control | Brentuximab Vedotin Plus Rituximab Plus Bendamustine |
|---|---|---|
| Overall Survival (OS) | 14.3 (3.9 to 18) | 6.5 (1.9 to 11.9) |
All AEs are included in the summaries, unless treatment-emergent is specified.
| Participants | Rituximab, Bendamustine Control | Brentuximab Vedotin Plus Rituximab Plus Bendamustine |
|---|---|---|
| Treatment-Emergent Adverse Event | 11 | 13 |
| Treatment-Related Adverse Event | 10 | 13 |
| Brentuximab Vedotin-Related Adverse Event | 0 | 11 |
| Rituximab-Related Adverse Event | 6 | 10 |
| Bendamustine-Related Adverse Event | 10 | 13 |
| Adverse Event with Outcome of Death | 0 | 1 |
| Serious Adverse Event | 3 | 8 |
| Treatment-Related Serious Adverse Event | 3 | 3 |
| Adverse Event Leading to Dose Delay | 3 | 0 |
| Adverse Event Leading to Treatment Discontinuation | 1 | 5 |
| Grade 3-5 Treatment-Emergent Adverse Event | 4 | 11 |
Collected over 1 year. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rituximab, Bendamustine Control | 2/12 (16.7%) | 3/12 (25%) | 11/12 (91.7%) |
| Brentuximab Vedotin Plus Rituximab Plus Bendamustine | 5/13 (38.5%) | 8/13 (61.5%) | 13/13 (100%) |
| Event | Rituximab, Bendamustine Control | Brentuximab Vedotin Plus Rituximab Plus Bendamustine |
|---|---|---|
| SepsisInfections and infestations | 0/12 | 2/13 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/12 | 0/13 |
| PyrexiaGeneral disorders | 1/12 | 1/13 |
| General physical health deteriorationGeneral disorders | 1/12 | 0/13 |
| Transient ischaemic attackNervous system disorders | 1/12 | 0/13 |
| InfectionInfections and infestations | 0/12 | 1/13 |
| Kidney infectionInfections and infestations | 0/12 | 1/13 |
| LymphangitisInfections and infestations | 0/12 | 1/13 |
| PneumoniaInfections and infestations | 0/12 | 1/13 |
| Pneumonia viralInfections and infestations | 0/12 | 1/13 |
| Event | Rituximab, Bendamustine Control | Brentuximab Vedotin Plus Rituximab Plus Bendamustine |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 2/12 | 6/13 |
| NauseaGastrointestinal disorders | 3/12 | 5/13 |
| VomitingGastrointestinal disorders | 1/12 | 5/13 |
| Abdominal painGastrointestinal disorders | 0/12 | 4/13 |
| PyrexiaGeneral disorders | 1/12 | 4/13 |
| HypokalaemiaMetabolism and nutrition disorders | 0/12 | 4/13 |
| AnaemiaBlood and lymphatic system disorders | 3/12 | 2/13 |
| NeutropeniaBlood and lymphatic system disorders | 3/12 | 1/13 |
| AstheniaGeneral disorders | 2/12 | 3/13 |
| FatigueGeneral disorders | 2/12 | 3/13 |
| Age, Categorical(Participants) | Rituximab, Bendamustine Control | Brentuximab Vedotin Plus Rituximab Plus Bendamustine | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 6 | 4 | 10 |
| >=65 years | 6 | 9 | 15 |
| Age, Continuous(years) | Rituximab, Bendamustine Control | Brentuximab Vedotin Plus Rituximab Plus Bendamustine | Total |
|---|---|---|---|
| Median | 64.5 (47 to 85) | 68.0 (40 to 79) | 68.0 (40 to 85) |
| Sex: Female, Male(Participants) | Rituximab, Bendamustine Control | Brentuximab Vedotin Plus Rituximab Plus Bendamustine | Total |
|---|---|---|---|
| Female | 8 | 6 | 14 |
| Male | 4 | 7 | 11 |
| Ethnicity (NIH/OMB)(Participants) | Rituximab, Bendamustine Control | Brentuximab Vedotin Plus Rituximab Plus Bendamustine | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 1 | 3 |
| Not Hispanic or Latino | 7 | 10 | 17 |
| Unknown or Not Reported | 3 | 2 | 5 |
| Race (NIH/OMB)(Participants) | Rituximab, Bendamustine Control | Brentuximab Vedotin Plus Rituximab Plus Bendamustine | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 9 | 11 | 20 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 3 | 2 | 5 |
| Region of Enrollment(participants) | Rituximab, Bendamustine Control | Brentuximab Vedotin Plus Rituximab Plus Bendamustine | Total |
|---|---|---|---|
| United States | 2 | 3 | 5 |
| Czechia | 1 | 0 | 1 |
| Poland | 1 | 0 | 1 |
| Italy | 3 | 4 | 7 |
| United Kingdom | 1 | 4 | 5 |
| France | 4 | 2 | 6 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants) | Rituximab, Bendamustine Control | Brentuximab Vedotin Plus Rituximab Plus Bendamustine | Total |
|---|---|---|---|
| 0: Normal Activity | 7 | 6 | 13 |
| 1: Symptoms but ambulatory | 5 | 4 | 9 |
| 2: In bed less than 50% of the time | 0 | 3 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of Oct 2015, a primary completion of Sep 2017 and a completion of Sep 2017. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2018, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brentuximab Vedotin
Lymphoma, Large B-Cell, Diffuse →